Pharma channel feed

Cat­a­lyst Phar­ma's Fir­dapse bet on con­gen­i­tal myas­thenic syn­dromes turns sour

6 years ago
R&D

No­var­tis takes a hit as FDA or­ders a hold on Zol­gens­ma tri­als in wake of fresh safe­ty con­cerns

6 years ago
Cell/Gene Tx
FDA+

Al­ler­gan ties up Na­men­da loose ends with $750M set­tle­ment

6 years ago
FDA+

FDA re­vis­es guid­ance on post­mar­ket­ing stud­ies to re­flect ARIA sys­tem, SUP­PORT act

6 years ago
FDA+

Ver­tex fi­nal­ly makes NICE with Eng­land's NHS on CF ther­a­pies, but runs in­to hic­cup with pre­clin­i­cal kid­ney drug da­ta

6 years ago
R&D
FDA+

Pub­lic funds help late-stage de­vel­op­ment of about 25% of new drugs, study finds

6 years ago
R&D

From $0 to $12B in an in­stant. Here's why bio­phar­ma loves risky Alzheimer's stud­ies

6 years ago
Bioregnum
R&D

Glax­o­SmithK­line cel­e­brates an­oth­er Ze­ju­la win in late-line ovar­i­an can­cer — and an FDA nod for the HRD bio­mark­er

6 years ago

EY vet set to re­place re­tir­ing Am­gen CFO Meline

6 years ago
People

J&J's block­buster Ste­lara wins US ap­proval for ul­cer­a­tive col­i­tis

6 years ago
R&D
FDA+

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

6 years ago
R&D
FDA+

Alex­ion clinch­es aHUS ap­proval for Ul­tomiris as the clock ticks on Soliris con­ver­sion

6 years ago

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

6 years ago
R&D
FDA+

J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

6 years ago
FDA+

With biosim­i­lar threat un­der con­trol (for now), Roche sa­vors de­mand for its new drugs

6 years ago
R&D

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

6 years ago
R&D

Pa­tient ex­pe­ri­ence da­ta: Sanofi re­searchers call for more con­sis­ten­cy from FDA

6 years ago
FDA+

HR vi­o­la­tion push­es Re­vance co-founder out, vault­ing for­mer Zel­tiq chief to the helm

6 years ago
People

Pelosi drug pric­ing bill promis­es sav­ings, but could gag R&D — CBO analy­sis

6 years ago
R&D

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

6 years ago
R&D

Re­searchers find 15% of tri­als could be repli­cat­ed us­ing re­al world da­ta

6 years ago
R&D

In re­ver­sal, NICE backs Rubra­ca af­ter Clo­vis agrees to a price cut

6 years ago
FDA+

Drug price hikes, with­out jus­ti­fi­able new ev­i­dence of ben­e­fit — ICER analy­sis

6 years ago
R&D

Dif­ferin mak­er Gal­der­ma wins FDA ap­proval for a new retinoid for ac­ne

6 years ago
FDA+
First page Previous page 260261262263264265266 Next page Last page
A service from the Financial Times